Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis
Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis
About this item
Full title
Author / Creator
van den Elskamp, IJ , Lembcke, J , Dattola, V , Beckmann, K , Pohl, C , Hong, W , Sandbrink, R , Wagner, K , Knol, DL , Uitdehaag, B and Barkhof, F
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background
MRI is often used as primary outcome measure in phase II clinical trials in multiple sclerosis (MS). Since persistent T1 hypointense lesions are a surrogate parameter for axonal damage and demyelination, they may serve as a marker for monitoring the efficacy of neuroprotective drugs. At present, a power analysis using black hole (BH)...
Alternative Titles
Full title
Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_69295850
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_69295850
Other Identifiers
ISSN
1352-4585
E-ISSN
1477-0970
DOI
10.1177/1352458507087842
